Dihydropyrimidine Dehydrogenase (DPYD) Genotyping
The dihydropyrimidine dehydrogenase enzyme (DPD, encoded by the gene DPYD) plays a key role in pyrimidine (uracil and thymidine) metabolism and in the metabolism of fluoropyrimidines. The DPYD gene is highly polymorphic with more than 15 variant alleles identified. Although 15 variants are identified, not all might directly impact function of the enzyme in pyrimidine metabolism. In addition to the DPYD1 allele, which is considered wild-type and encodes a fully active enzyme (normal), alleles DPYD 4, 5, 6 and 9A are also considered fully active alleles and will not affect enzyme function at all. Alleles 2A and *13 and the allele with mutation rs67376798 T>A are nonfunctional alleles as encode an inactive enzyme or nonfunctional enzyme. The allele with the mutation rs115232898 T>C encodes a partially active enzyme and is referred to as a reduced function allele. There are several other identified variants that also decrease DPD enzyme activity including those found in the DPYD 3, 8, 9B, 10, 11 and 12 alleles.
Based on the variation detected, individuals with two fully functional alleles have a normal (or high) DPD activity (normal metabolizer). Individuals with one fully functional allele and one non-functional allele have a partial DPD deficiency (intermediate metabolizer). Individuals with two nonfunctional alleles have a complete DPD deficiency (poor metabolizer). Individuals with one reduced-function allele and one nonfunctional allele as well as individuals with two reduced-function alleles are provisionally classified as having a complete DPD deficiency (poor metabolizer). The DPYD genotyping assay identifies some common variants that are associated with variability in DPD enzyme activity, which has important pharmacological and toxicological implications for all fluoropyrimidine drugs used in the treatment of cancer.
There is substantial evidence linking the DPYD polymorphisms to variability in the pharmacological and safety profiles of the following therapies used in the treatment of cancer: fluorouracil (Efudex, Adrucil, Carac, Fluoroplex), capecitabine (Xeloda), and tegafur (Uftoral). Decreased DPYD activity is associated with a greater than 4-fold risk of severe or fatal toxicity from standard doses of these fluoropyrimidine drugs. 5-Fluorouracil (5-FU) is the most frequently used chemotherapeutic drug for the treatment of many types of cancer, particularly colorectal adenocarcinoma.
- Monitor pharmacological efficacy and safety of the chemotherapy used in the treatment of cancer: fluorouracil (Efudex, Adrucil, Carac, Fluoroplex), capecitabine (Xeloda), and tegafur (Uftoral)
- Therapy monitoring and adjustment
Nonfunctional (lost function): Alleles *2A and *13, and alleles with rs67376798 T>A.
Reduced function (partially functional): The allele with the mutation rs115232898 T>C and Alleles *3, *8, *9B, *10, *11 and *12
Decreased DPYD activity is associated with a greater than 4-fold risk of severe or fatal toxicity from standard doses of these fluoropyrimidine.
Activity Score: 2 Normal Metabolizer Consistent with a typical DPD activity
Acceptable specimens include buccal swab and peripheral blood (EDTA) or saliva.
Buccal swabs can be collected by rubbing the inside of the cheeks with a swab (similar to a Q-tip and generally 4 swabs). The swabs are transported to the laboratory in a liquid medium (see manufacturer guidelines for details) or dry swab.
Peripheral blood is collected through venipuncture. A minimum of 5-10 ml of whole blood is required. The specimen is collected in a lavender top (EDTA) tube.
Specimen Stability (Blood specimens):
- Ambient: 5 days
- Refrigerated: 7 days
- Clin Pharmacol Ther. 2013 Dec;94(6):640-5. [PMID: 23988873]
- Lancet Oncol. 2015 Dec;16(16):1639-50. [PMID: 26603945]
- Mol Cancer Ther. 2006 Nov;5(11):2895-904. [PMID: 17121937]
- Pharmacogenomics. 2002 Jul;3(4):485-92. [PMID: 12164772]
- Cancer Res. 2014 May 1;74(9):2545-54. [PMID: 24648345]